ArticleRegenerative biomaterials2026
Engineered bilayer hydrogel with spatiotemporal drug and oxygen delivery for diabetic wound microenvironment reprogramming.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- A self-oxygenating polyphenol-nanozyme hydrogel remodels the inflammatory microenvironment for diabetic wound healing.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impaired healing of diabetic wounds primarily stems from persistent inflammation, a hypoxic microenvironment, and heightened susceptibility to infection. However, most existing studies focus on simple functional stacking, rather than aligning with the dynamic pathological repair process, which hinders the maximization of therapeutic efficacy of the repair materials. In this study, an intelligently responsive, bilayer anti-fouling nanocomposite hydrogel (Ca@Q-E@SGH) was developed for spatiotemporally synergistic therapy via spatiotemporal drug and oxygen delivery strategies. Its core component (Ca@Q-E) consists of calcium peroxide encapsulated by phenylboronic acid-modified quaternary ammonium chitosan, with epigallocatechin gallate (EGCG) linked via boronate esters. This dynamic bond enables ROS/glucose-responsive EGCG release to reprogram macrophages from the M1 to M2 phenotype, mitigating early-stage inflammation. As the matrix degrades, sustained oxygen is released from CaO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.